NeuroPace cuts 2026 revenue guide and falls on three downgrades
NeuroPace reduced its 2026 revenue forecast to $91M-$92M from $99.5M-$101.5M, leading to three downgrades. Health Care sector saw high activity but modest gains, with XLV up 2.21%. Larimar and Altimmune insiders made purchases, and InspireMD priced a $37.5M offering.
How this was made
The 30-second read
Why it matters
The guidance cut and downgrades triggered a near‑48% price drop, indicating heightened risk for the stock and potential spill‑over to other small‑cap med‑tech names.
Market read
The article highlights a significant price move for NPCE driven by a fresh guidance cut and multiple downgrades, making it a high‑impact, actionable event for traders.
What to watch
The net loss narrowed and adjusted EBITDA turned positive, which may soften the downside if investors focus on profitability improvement.
Background
NeuroPace is a niche epilepsy device maker listed on NASDAQ. The company reported Q3 results, trimmed its full‑year revenue outlook, and was downgraded by three brokerages.
Ticker impact
NeuroPace cut its 2026 revenue guidance to $91M‑$92M and was hit with three downgrades, sending the stock down about 48% in Friday's session.
likely continued downside as investors price in lower revenue expectations
The revenue range was reduced by roughly $9M and three broker houses downgraded the stock, causing a sharp intraday drop; no offsetting positive catalyst is present.
Market effects
Health Care sector may see modest drag as the most active small‑cap med‑tech name posted a sharp decline.
U.S. small‑cap and biotech investors likely to reassess exposure to similar neuro‑technology firms.
Limited to U.S. markets; no broader macro impact.
Counterpoint
If the IGE indication proceeds on schedule, the revenue shortfall could be temporary, offering a buying opportunity at lower levels.
Key entities
- CompanyNeuroPace
NASDAQ‑listed epilepsy device maker (ticker NPCE).
- BrokerWells Fargo
Downgraded NPCE to Equal Weight.
- BrokerLeerink Partners
Downgraded NPCE to Market Perform.
- BrokerJPMorgan
Downgraded NPCE to Neutral.


